• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Eli Lilly

Novartis
Pharma

SABCS: Novartis gives update on Kisqali in early breast cancer

While Kisqali’s updated invasive disease-free survival benefit looks nearly identical to the result shared at ASCO, some subtle shifts have emerged.
Angus Liu Dec 8, 2023 9:15am
Eli Lilly

Lilly's Verzenio barely misses overall survival goal in 1L

Dec 6, 2023 10:00am
Jaypirca

Lilly's Jaypirca blazes CLL trail with FDA approval

Dec 4, 2023 4:11am
Ozempic

Florida pharmacies selling GLP-1 knockoffs face Novo complaints

Nov 30, 2023 10:58am
deal

Teva, Eli Lilly agree to dismiss one of Teva's patent cases

Nov 28, 2023 12:07pm
Q3

No surprise: Lilly, Novo Nordisk were top revenue gainers in Q3

Nov 28, 2023 3:00am

Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy